TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03264807

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 lymphadenectomy
Description: Subtotal gastrectomy with D2 lymphadenectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) is conventional surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 and #14v lymphadenectomy
Description: Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and #14v lymphadenectomy is experimental surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
Study: NCT04211116

Intervention type: DEVICE
Intervention: Central venous line insertion
Description: Pediatric patients indicated to central venous line insertion
Study: NCT02936908

Intervention type: OTHER
Intervention: Ventilatory support
Description: Initiation of mechanical ventilatory support, invasive or non-invasive, Or modification of mechanical ventilatory support (modification of the parameters of the device, change of material, switch from non-invasive to invasive)
Study: NCT00770601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study: NCT03263260

Intervention type: DEVICE
Intervention: implant
Description: coronary stent implantation
Study: NCT02692001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention MealTrain menu
Description: Nutrition education was incorporated using an interpretive traffic light system menu labeling. Dietitians categorized current menu items as green, yellow and red based on fiber, added sugar, saturated fats, and sodium content. A section entitled Eat like a superhero was created to prime children to consider what their potential role models choose, and incorporates descriptive names, suggest sample breakfast, lunch and dinner meals with photographs of portion sizes. Original cartoon female grapes and male broccoli superhero characters were created to employ promotional techniques specifically to promote fruits and vegetable selection for boys and girls.
Study: NCT02716181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Атопик Soothing Cream
Description: Topical application of a study cream to involved skin areas twice a day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Атопик Soothing Cream
Description: Topical application of a study cream to involved skin areas twice a day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Атопик Soothing Cream
Description: Topical application of a study cream to involved skin areas twice a day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Атопик Soothing Cream
Description: Topical application of a study cream to involved skin areas twice a day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Topical application of a study placebo cream to involved skin areas twice a day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Topical application of a study placebo cream to involved skin areas twice a day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application of a study placebo cream to involved skin areas twice a day.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application of a study placebo cream to involved skin areas twice a day.
Study: NCT02290977

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Scheduled interval TACE - RT
Description: RT will be administered at 2 weeks after TACE in HCC combined PVTT
Study: NCT04651491

Intervention type: DRUG
Intervention: Kagocel
Description: The researchers prescribed antiviral medications, including Kagocel, according to routine clinical practice. Patients who were assigned Kagocel were invited to participate in the study.~Kagocel administration:~1. for children from 3 to 6 years old (n=41): In the first 2 days - 1 tablet 2 times a day, in the next 2 days - 1 tablet once a day. Total for the course of administration 6 tablets within the period of 4 days.~2. for children from 6 years old (n=39) - administered in the first 2 days - 1 tablet 3 times a day, in the next 2 days - 1 tablet 2 times a day. Total for the course of administration 10 tablets within the period of 4 days.
Study: NCT02205528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0090-2746
Description: NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
Study: NCT04140045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water intake
Description: Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water intake
Description: Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise
Study: NCT02328534

Intervention type: BEHAVIORAL
Intervention: Blastocyst Formation Rate
Description: Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.

Intervention type: BEHAVIORAL
Intervention: Blastocyst Formation Rate
Description: Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.

Intervention type: PROCEDURE
Intervention: Blastocyst Rate
Description: Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.~Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.

Intervention type: PROCEDURE
Intervention: Blastocyst Rate
Description: Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.~Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.

Intervention type: PROCEDURE
Intervention: Pregnancy Rate
Description: All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.
Study: NCT04016545

Intervention type: DEVICE
Intervention: Low profile endoprothesis (Navion Medtronic, NBS Low Profile Bolton Terumo)
Description: Aortic aneurysm exclusion through endovascular procedure
Study: NCT04220411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR100DP1
Description: topical ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR100DP1
Description: topical ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR100DP1
Description: topical ointment
Study: NCT02328534

Intervention type: PROCEDURE
Intervention: Pregnancy Rate
Description: All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.
Study: NCT02466009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
Study: NCT02741765

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: Subjects will participate in daily sessions of sham-rTMS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real rTMS
Description: Subjects will participate in a combination of rTMS

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised aerobic exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Study: NCT01561053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin 5%
Description: Therapeutic plasma exchange with human albumin 5%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin 5%
Description: Therapeutic plasma exchange with human albumin 5%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin 5%
Description: Therapeutic plasma exchange with human albumin 5%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin 20%
Description: Low volume plasma exchange with human albumin 5%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin 20%
Description: Low volume plasma exchange with human albumin 5%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin 20%
Description: Low volume plasma exchange with human albumin 5%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoglobulin
Description: Intravenous human immunoglobulin 5%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoglobulin
Description: Intravenous human immunoglobulin 5%
Study: NCT02516202

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Dispensed in visually identical tube and gel form to Replens.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo gel
Description: Dispensed in visually identical tube and gel form to Replens.
Study: NCT04220411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR100DP1
Description: topical ointment
Study: NCT04059146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Education and Exercise
Description: Participants will be randomly assigned to a pain education group, following biopsychosocial model, or standard of care education, following biomedical model. The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain. Participants will be given weekly online exercises to promote engagement with the material, give individual feedback to participants, and assess understanding. In person sessions with the physical therapist will reinforce self-learning and application to a home exercise program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education and Exercise
Description: The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage. The videos, handouts, and exercises will be equivalent to the pain education group in terms of time and learning requirements.
Study: NCT05175066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: For patients who were candidates to start therapy with anthracycline, bisoprolol was administrated as explained before to determine the effect of this drug on the reduction of anthracycline-induced cardiomyopathy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets with similar shape and size and color to bisoprolol were given to the patients whom undergone chemotherapy with anthracyclines to compare the effects between two groups.
Study: NCT05134207

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral carbohydrate solution
Description: Patients in the intervention group; Preop oral carbohydrate solution was ingested orally twice within 10 minutes, as 800 ml at 24:00 the night before the surgery and 400 ml at 06:00 2 hours before the surgery.
Study: NCT03467087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myopuls 2000D
Description: Device: Myopuls 2000D (Curatec Services GmBH, 47443 Moers, Germany)
Study: NCT03054662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education of patients and caregivers about haemophilia and carriers of haemophilia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education of patients and caregivers about haemophilia and carriers of haemophilia.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Improve biological diagnosis and follow-up of haemophilia
Description: train the laboratory to the diagnosis ans follow-up un haemophilia

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Improve biological diagnosis and follow-up of haemophilia
Description: train the laboratory to the diagnosis ans follow-up un haemophilia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Implement haemostatic non substitutive care of haemophilia
Description: Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Implement haemostatic non substitutive care of haemophilia
Description: Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers
Study: NCT00529529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol 50 μg
Description: Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salmeterol
Description: Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to salmeterol
Description: Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
Study: NCT03489460

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GAD
Description: Survey responses will be merged with objective GAD data (sleep time, time in deep sleep, physical activity) which will assist in developing message design formats for message testing.
Study: NCT02033720

Intervention type: OTHER
Intervention: No treatment
Description: No therapeutic hypothermia was induced.

Intervention type: OTHER
Intervention: No treatment
Description: No therapeutic hypothermia was induced.

Intervention type: OTHER
Intervention: No treatment
Description: No therapeutic hypothermia was induced.

Intervention type: OTHER
Intervention: Therapeutic hypothermia
Description: Hypothermia was induced after successful resuscitation from cardiac arrest.

Intervention type: OTHER
Intervention: Therapeutic hypothermia
Description: Hypothermia was induced after successful resuscitation from cardiac arrest.

Intervention type: OTHER
Intervention: Therapeutic hypothermia
Description: Hypothermia was induced after successful resuscitation from cardiac arrest.
Study: NCT01824368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis Procedure (FEC)
Description: The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.~1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.~Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex.
Study: NCT04654299

Intervention type: PROCEDURE
Intervention: External biliary stent
Description: The biliary stent consisted of a multi-perforated, natural rubber tube, measuring 3.5 mm in diameter, that we placed transanastomotically, with exteriorization sited at 20 cm utilizing the Witzel jejunostomy approach
Study: NCT00422227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept , Methotrexate
Description: * Etanercept: 25 mg twice weekly over 16 weeks, SC~* Methotrexate: \> 7.5 mg/week and no more than 25 mg/week, PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide
Description: * Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~* Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~* Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~* Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily
Study: NCT00430703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: body weight support treadmill training
Description: Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: body weight support treadmill training
Description: Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
Study: NCT01449604

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: stereotactic radiotherapy
Description: Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: stereotactic radiosurgery
Description: Radio surgery 12 Gy